The US Food and Drug Administration (FDA) has granted narrow approval for Roche’s cancer drug Tecentriq, a first for any kind of breast cancer immunotherapy. Tecentriq, aimed at local advanced or metastatic triple-negative breast cancer, binds with the PD-L1 molecule and prevents it from stopping T-cells attacking tumours. There is not enough data from the ongoing IMpassion 130 clinical trial to determine whether Tecentriq can extend life expectancy in triple negative breast cancer patients beyond later this year, and further FDA approval could depend on final survival analysis data due to be released the median 25 months.
The US Food and Drug Administration (FDA) has granted narrow approval for Roche’s cancer drug Tecentriq, a first for any kind of breast cancer immunotherapy. Tecentriq, aimed at local advanced or metastatic triple-negative breast cancer, binds with the PD-L1 molecule and prevents it from stopping T-cells attacking tumours. There is not enough data from the ongoing IMpassion 130 clinical trial to determine whether Tecentriq can extend life expectancy in triple negative breast cancer patients beyond the median 25 months, and further FDA approval could depend on final survival analysis data due to be released later this year.